TCT-846 Clinical Outcomes in Patients Treated With the Fully Absorbable, Everolimus-Eluting RENUVIATM Scaffold: Primary Endpoint Results from the FAST First Human Use Study

Methods Subjects with single de novo native coronary artery lesion (length:<=12mm; reference vessel diameter:>=2.75mm and <=3.25mm) were enrolled in this prospective, multi-center, single arm feasibility study (N=33). Conclusion Bioabsorbable scaffold technology represents a promising strat...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 70; no. 18; p. B342
Main Authors Seneviratne, Sujith, Erglis, Andrejs, Walters, Darren, Whitbourn, Robert, Layland, Jamie, Stewart, Jim, El-Jack, Seif, Christen, Thomas, Allocco, Dominic, Meredith, Ian
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 31.10.2017
Elsevier Limited
Subjects
Cardiology
Cardiovascular
Cardiovascular disease
Coronary artery
Coronary vessels
Feasibility studies
Inhibitor drugs
Stents
Online AccessGet full text

Cover

More Information
Summary:Methods Subjects with single de novo native coronary artery lesion (length:<=12mm; reference vessel diameter:>=2.75mm and <=3.25mm) were enrolled in this prospective, multi-center, single arm feasibility study (N=33). Conclusion Bioabsorbable scaffold technology represents a promising strategy for treatment of coronary artery disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.1054